| SALEK, Cyril, František FOLBER, Štěpán HRABOVSKÝ, Zdenek KORISTEK, Jan M HORACEK, Eva FRONKOVA, Petr SOUKUP, Katerina BENKOVA, Petr CETKOVSKY, Jan TRKA and Michael DOUBEK. Single Cycle of Blinatumomab Followed By High-Dose Chemotherapy in the Induction Therapy for Ph-Negative Acute Lymphoblastic Leukemia in Adults. Primary Endpoint Analysis of the Blina-Cell Trial. 2022. Available from: https://dx.doi.org/10.1182/blood-2022-157361. |
Other formats:
BibTeX
LaTeX
RIS
@proceedings{2361066,
author = {Salek, Cyril and Folber, František and Hrabovský, Štěpán and Koristek, Zdenek and Horacek, Jan M and Fronkova, Eva and Soukup, Petr and Benkova, Katerina and Cetkovsky, Petr and Trka, Jan and Doubek, Michael},
doi = {http://dx.doi.org/10.1182/blood-2022-157361},
keywords = {blinatumomab; high-dose chemotherapy; acute lymphoblastic leukemia},
language = {eng},
title = {Single Cycle of Blinatumomab Followed By High-Dose Chemotherapy in the Induction Therapy for Ph-Negative Acute Lymphoblastic Leukemia in Adults. Primary Endpoint Analysis of the Blina-Cell Trial},
url = {https://ashpublications.org/blood/article/140/Supplement%201/3258/490622/Single-Cycle-of-Blinatumomab-Followed-By-High-Dose},
year = {2022}
}
TY - CONF
ID - 2361066
AU - Salek, Cyril - Folber, František - Hrabovský, Štěpán - Koristek, Zdenek - Horacek, Jan M - Fronkova, Eva - Soukup, Petr - Benkova, Katerina - Cetkovsky, Petr - Trka, Jan - Doubek, Michael
PY - 2022
TI - Single Cycle of Blinatumomab Followed By High-Dose Chemotherapy in the Induction Therapy for Ph-Negative Acute Lymphoblastic Leukemia in Adults. Primary Endpoint Analysis of the Blina-Cell Trial
KW - blinatumomab
KW - high-dose chemotherapy
KW - acute lymphoblastic leukemia
UR - https://ashpublications.org/blood/article/140/Supplement%201/3258/490622/Single-Cycle-of-Blinatumomab-Followed-By-High-Dose
N2 - Background: Blinatumomab induces a high proportion of complete molecular responses in relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) and ALL with persistent or recurrent measurable residual disease (MRD) after initial therapy. However, responses are generally short if they are not followed by allogeneic stem cell transplantation (HSCT). We infer that blinatumomab needs to be incorporated sequentially into the early phase of treatment to enhance rates of MRD negativity, lower the need of HSCT and improve survival.
ER -
SALEK, Cyril, František FOLBER, Štěpán HRABOVSKÝ, Zdenek KORISTEK, Jan M HORACEK, Eva FRONKOVA, Petr SOUKUP, Katerina BENKOVA, Petr CETKOVSKY, Jan TRKA and Michael DOUBEK. \textit{Single Cycle of Blinatumomab Followed By High-Dose Chemotherapy in the Induction Therapy for Ph-Negative Acute Lymphoblastic Leukemia in Adults. Primary Endpoint Analysis of the Blina-Cell Trial}. 2022. Available from: https://dx.doi.org/10.1182/blood-2022-157361.
|
